# Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

> **NCT05349617** · PHASE3 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 413 (actual)

## Conditions studied

- Chikungunya Virus

## Interventions

- **BIOLOGICAL:** CHIKV VLP/adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05349617
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-12
- **Primary completion:** 2023-06-19
- **Final completion:** 2023-08-08
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349617, "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05349617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*